Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0954A · 2 trials · 1 indication
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration (Day 56 ± 7 days).
| Arm | Type | Description |
|---|---|---|
| MK-954H (L50/H12.5) | ACTIVE_COMPARATOR | One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension) |
| MK-0954A (L100/H12.5) | EXPERIMENTAL | One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension |
| MK-0954A | EXPERIMENTAL | Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks. |
| Losartan | ACTIVE_COMPARATOR | Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks. |
| Name | Type | Description |
|---|---|---|
| MK-0954A | DRUG | Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily |
| MK-954H | DRUG | Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily |
| Placebo to MK-0954A | DRUG | Placebo tablet to match MK-0954A, once daily |
| Placebo to MK-954H | DRUG | Placebo tablet to match MK-954H, once daily |
| Losartan | DRUG | Tablet containing losartan potassium (100 mg), once daily |
| Placebo to losartan 100 mg | DRUG | Placebo tablet to match losartan 100 mg, once daily |
| Placebo to losartan 50 mg | DRUG | Placebo tablet to match losartan 50 mg, once daily |
Inclusion criteria: * Participant has a diagnosis of essential hypertension. * Participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication. * Participant has a mean trough SiDBP of \>=90mmHg and \< ...
MK-0954A is an investigational small molecule being developed for the treatment of hypertension, also known as high blood pressure. It is currently in Phase 3 clinical development and has been studied in patients with essential hypertension.
MK-0954A is being developed by Organon & Co. (NYSE: OGN). The company is conducting Phase 3 clinical trials to evaluate the drug's safety and efficacy in patients with hypertension.
MK-0954A is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, but the drug remains under investigation for hypertension.
MK-0954A has been studied in two completed Phase 3 trials: NCT01307033, a long-term safety study in patients with essential hypertension, and NCT01307046, a study in Japanese patients with essential hypertension not adequately controlled with losartan. Both trials were randomized, double-blind, and active-controlled.
No, MK-0954A is not the same as losartan. In one clinical trial (NCT01307046), MK-0954A was studied in Japanese patients whose hypertension was not adequately controlled with losartan, indicating that losartan is a separate medication used as a comparator or prior treatment.